Developed by specialist healthcare communications agency OVID Health, the Patient Partnership Index is the UK's leading initiative in patient-centric communications and advocacy. The Index offers pharmaceutical and biotech companies an opportunity to showcase, benchmark and evaluate the quality of their communications and advocacy with patient groups.

Entries are assessed by the Index’s expert panel of judges against the following six metrics:

Engagement, Co-creation, Empowerment, Transparency, Innovation, and Impact. These metrics were developed by OVID Health following consultation with pharmaceutical companies and patient organisations, as well as independent experts and academics.

Insights and ideas from this year’s Index will be explored in the free virtual event “Empowering Tomorrow’s Patients”, taking place 8:30-10 am, Tuesday 5 July, 2022

This event will bring together senior leaders and key figures from pharmaceutical companies and patient groups, alongside this year’s judges, to explore the future of patient-centricity and how patient partnerships have risen to the challenges of the COVID-19 pandemic. To book your place at the event, register via the online event page here.

The Index is pleased to announce the results for 2022 as follows:

Gold Standard

Galapagos Biotech

Gilead Sciences

Gilead Sciences Ltd UK and Ireland

Medicine Discovery Catapult (MDC)

Novo Nordisk



Silver Standard

Eli Lilly and Company

Gilead Sciences Ltd UK and Ireland



LEO Pharma

Novo Nordisk


Vifor Pharma

Finalist Standard

Novo Nordisk



This year, Index judges were Sarah Woolnough, CEO of Asthma UK and British Lung Foundation; Jenny Ousbey, Managing Director of OVID Health; Colette Goldrick, Executive Director of the ABPI; and John James OBE, CEO of the Sickle Cell Society.

Commenting on the results, chair of Judges Jenny Ousbey said: “I was delighted to see a record number of entries to this year’s Patient Partnership Index, which is testament to the fantastic partnerships being developed by pharma and patient groups. I was particularly struck by the number of outstanding submissions showcasing successful and enduring long-term relationships between pharmaceutical companies and patient groups. These partnerships will undoubtedly help improve patient outcomes, an objective at the heart of the PPI. On behalf of all the judges, I would like to congratulate all those who entered, in particular those who were awarded gold standard and look forward to discussing the many inspiring innovations and insights from this year’s entries at our panel event in July.”

To find out more about the Patient Partnership Index 2022, visit the Index website or contact the team at